ALAN SWANN to Drug Administration Schedule
This is a "connection" page, showing publications ALAN SWANN has written about Drug Administration Schedule.
Connection Strength
0.247
-
MDMA (ecstasy) modulates locomotor and prefrontal cortex sensory evoked activity. Brain Res. 2009 Dec 11; 1302:175-82.
Score: 0.017
-
Descending glutamatergic pathways of PFC are involved in acute and chronic action of methylphenidate. Brain Res. 2009 Dec 08; 1301:68-79.
Score: 0.017
-
Adolescent and adult male spontaneous hyperactive rats (SHR) respond differently to acute and chronic methylphenidate (Ritalin). Int J Neurosci. 2009; 119(1):40-58.
Score: 0.016
-
Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. Brain Res. 2007 May 11; 1145:66-80.
Score: 0.014
-
Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains. Brain Res Bull. 2006 Dec 11; 71(1-3):301-10.
Score: 0.014
-
A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006 Oct; 67(10):1501-10.
Score: 0.014
-
Chronic methylphenidate modulates locomotor activity and sensory evoked responses in the VTA and NAc of freely behaving rats. Neuropharmacology. 2006 Sep; 51(3):546-56.
Score: 0.014
-
Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005 Mar; 162(3):621-4.
Score: 0.012
-
Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005 Mar; 66(3):323-30.
Score: 0.012
-
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004 Jan; 65(1):114-9.
Score: 0.011
-
Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology. 2003 Jul; 28(7):1374-82.
Score: 0.011
-
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003 Mar; 64(3):288-94.
Score: 0.011
-
Valproate prevents the induction and the expression of MK-801 sensitization. Brain Res. 2002 Nov 08; 954(2):151-9.
Score: 0.011
-
Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry. 2002 Apr; 63(4):288-99.
Score: 0.010
-
Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. J Clin Psychiatry. 2001 Jun; 62(6):439-47.
Score: 0.010
-
Methylphenidate sensitization is modulated by valproate. Life Sci. 2001 May 25; 69(1):47-57.
Score: 0.010
-
Valproate modulates the expression of methylphenidate (ritalin) sensitization. Brain Res. 2000 Aug 25; 874(2):216-20.
Score: 0.009
-
Diurnal differences in sensitization to methylphenidate. Brain Res. 2000 May 02; 864(1):24-39.
Score: 0.009
-
A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000 May; 57(5):481-9.
Score: 0.009
-
Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996 Jun; 153(6):765-70.
Score: 0.007
-
Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994 Mar 23-30; 271(12):918-24.
Score: 0.006
-
Treatment of trichotillomania with fluoxetine. J Clin Psychiatry. 1991 Jun; 52(6):282.
Score: 0.005